Curi RMB Capital LLC Raises Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Curi RMB Capital LLC grew its stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 47.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 149,577 shares of the company’s stock after acquiring an additional 48,202 shares during the quarter. Curi RMB Capital LLC owned about 0.07% of Allogene Therapeutics worth $419,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Primecap Management Co. CA boosted its holdings in Allogene Therapeutics by 4.1% in the second quarter. Primecap Management Co. CA now owns 5,670,226 shares of the company’s stock worth $13,212,000 after purchasing an additional 221,840 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Allogene Therapeutics by 76.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,177,619 shares of the company’s stock worth $18,675,000 after acquiring an additional 1,806,147 shares during the period. Perceptive Advisors LLC purchased a new stake in Allogene Therapeutics during the second quarter valued at $6,349,000. Dimensional Fund Advisors LP lifted its holdings in Allogene Therapeutics by 24.8% in the second quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock valued at $5,944,000 after acquiring an additional 507,021 shares during the period. Finally, Lynx1 Capital Management LP purchased a new position in Allogene Therapeutics in the second quarter worth about $5,192,000. 83.63% of the stock is currently owned by institutional investors.

Allogene Therapeutics Trading Down 7.7 %

Shares of ALLO opened at $2.27 on Friday. The business’s 50 day moving average is $2.75 and its 200 day moving average is $2.66. Allogene Therapeutics, Inc. has a 12-month low of $2.01 and a 12-month high of $5.78. The company has a market capitalization of $475.95 million, a PE ratio of -1.46 and a beta of 0.84.

Analyst Ratings Changes

ALLO has been the topic of several recent research reports. Piper Sandler lowered their price objective on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday. Oppenheimer initiated coverage on shares of Allogene Therapeutics in a research note on Thursday, August 8th. They set an “outperform” rating and a $11.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Allogene Therapeutics in a research note on Friday, November 8th. Canaccord Genuity Group lowered their target price on Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. Finally, William Blair restated an “outperform” rating on shares of Allogene Therapeutics in a research report on Thursday. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $9.73.

Allogene Therapeutics Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).